内容紹介
Efficacy of Chemotherapy Combined with Bevacizumab for Unresectable Advanced or Recurrent Colorectal Cancer
Summary
Systemic treatment for metastatic or advanced colorectal cancer(mCRC)has remarkably progressed during recent years. All previously untreated mCRC patients at our institution between November, 2007 and June, 2010 were retrospectively evaluated. Of 72 patients, 39 were treated with chemotherapy alone, and 33 were treated with chemotherapy plus bevacizumab(BV). The median progression-free survival(mPFS)was 329 days in the group given chemotherapy plus BV, compared with 209 days in the group given chemotherapy alone(p=0.0189). In sub-group analysis of those treated with chemotherapy plus BV, mPFS between 70 y/o≤and<70 y/o was not different(368 vs 306 days, respectively; p=0.7872). The relative dose intensity of oxaliplatin(L-OHP)was 80% in the group with FOLFOX+BV(n=15), and 92% with XELOX+BV(n=8). Chemotherapy with BV for previously untreated mCRC was well tolerated and effective.
要旨
進行・再発大腸癌患者に対する全身化学療法は近年大きく進歩している。2007年11月～2010年6月末までに当科にて受診した未治療進行・再発大腸癌患者をretrospectiveに検討した。全72例中,化学療法単独施行は39例,bevacizumab(BV)併用化学療法施行は33例であった。無増悪生存期(progression-free survival: PFS)中央値は,BV非併用群209日,併用群329日であった(p=0.0189)。BV併用群では,70歳以上,70歳未満の両群でPFS中央値に差は認められなかった(368日/306日,p=0.7872)。また,FOLFOX+BV療法群,XELOX+BV療法群では,oxaliplatin(L-OHP)のrelative dose intensityは,それぞれ80%(n=15),92%(n=8)であった。一次治療においてBV併用化学療法の治療成績は良好であった。
目次
Summary
Systemic treatment for metastatic or advanced colorectal cancer(mCRC)has remarkably progressed during recent years. All previously untreated mCRC patients at our institution between November, 2007 and June, 2010 were retrospectively evaluated. Of 72 patients, 39 were treated with chemotherapy alone, and 33 were treated with chemotherapy plus bevacizumab(BV). The median progression-free survival(mPFS)was 329 days in the group given chemotherapy plus BV, compared with 209 days in the group given chemotherapy alone(p=0.0189). In sub-group analysis of those treated with chemotherapy plus BV, mPFS between 70 y/o≤and<70 y/o was not different(368 vs 306 days, respectively; p=0.7872). The relative dose intensity of oxaliplatin(L-OHP)was 80% in the group with FOLFOX+BV(n=15), and 92% with XELOX+BV(n=8). Chemotherapy with BV for previously untreated mCRC was well tolerated and effective.
要旨
進行・再発大腸癌患者に対する全身化学療法は近年大きく進歩している。2007年11月～2010年6月末までに当科にて受診した未治療進行・再発大腸癌患者をretrospectiveに検討した。全72例中,化学療法単独施行は39例,bevacizumab(BV)併用化学療法施行は33例であった。無増悪生存期(progression-free survival: PFS)中央値は,BV非併用群209日,併用群329日であった(p=0.0189)。BV併用群では,70歳以上,70歳未満の両群でPFS中央値に差は認められなかった(368日/306日,p=0.7872)。また,FOLFOX+BV療法群,XELOX+BV療法群では,oxaliplatin(L-OHP)のrelative dose intensityは,それぞれ80%(n=15),92%(n=8)であった。一次治療においてBV併用化学療法の治療成績は良好であった。